This study is looking at two intravenous (IV) iron treatments, ferumoxytol and iron sucrose, for children aged 2 to 17 years old who have iron deficiency anemia (IDA). IDA means your body doesn't have enough iron to make healthy red blood cells. You might be able to join if you have IDA, defined by a hemoglobin level below 11.0 g/dL and certain iron levels (transferrin saturation below 20% or ferritin below 100 ng/mL), and if oral iron hasn't worked or isn't an option. The main goal is to see how much your hemoglobin levels change from the start of the study to Week 5. The study plans to enroll 75 participants.

Study design

This is a Phase 3, randomized, open-label study, meaning participants are randomly assigned to one of two treatments, and both you and your doctors will know which treatment you receive. About 75 children are expected to participate.

What's involved

You would receive either two doses of ferumoxytol or five doses of iron sucrose intravenously. You would be monitored at the study site for at least one hour after each infusion and have blood tests and safety checks through Week 5.

Compensation

Not stated in the trial record.

Follow-up

Your hemoglobin levels and safety will be monitored through Week 5 after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.